Surface-Exposed Pseudomonas Antigens for Vaccine Development
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for developing vaccines against Pseudomonas aeruginosa are time-consuming, labor-intensive, and costly, often focusing on abundant proteins that may not be immunoprotective, and are limited by the need for large quantities of antigens, especially for pathogens with large genomes.
Innovation Solution
Identification and utilization of novel, hitherto unknown putatively surface-exposed proteins from Pseudomonas aeruginosa as antigenic polypeptides for vaccine development, along with associated nucleic acids, vectors, and antibodies to induce immunity and diagnose infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If the empirical approach is used to identify protective antigens by testing abundant proteins, then the vaccine development process can be initiated, but the approach is time-consuming, labor-intensive, and costly
Solution Approach 1:
The patent applies preliminary action by using bioinformatics tools to predict and identify protective antigens before the empirical testing phase. The system analyzes genomic data and protein structures in advance to select candidate antigens, thereby reducing the time and resources required for subsequent experimental testing.
Solution Approach 2:
The patent uses computational models and digital representations of protein structures and genomic data to simulate and predict antigen behavior. This allows researchers to evaluate multiple candidate antigens virtually before producing physical samples, significantly reducing laboratory work and time investment.
2Ease of manufacture
If the empirical approach focuses on abundant proteins, then antigen identification can be simplified, but the abundant proteins may not be immunoprotective
Solution Approach 1:
The patent applies local quality by analyzing specific regions and properties of proteins rather than treating all proteins uniformly. The system evaluates local structural features, surface accessibility, and immunogenicity characteristics to identify proteins that are both abundant and likely to be immunoprotective, filtering out abundant proteins that lack protective properties.
Solution Approach 2:
The patent changes the parameters for protein evaluation from simple abundance metrics to a multi-parameter assessment including structural characteristics, surface exposure, immunogenicity scores, and protective potential. This transformed evaluation approach enables reliable identification of immunoprotective antigens among abundant proteins.
3Quantity of substance
If large quantities of antigens are required for vaccine development, then sufficient material for testing can be obtained, but the cost and complexity of production increase
Solution Approach 1:
The patent extracts and focuses on specific candidate antigens that are predicted to be immunoprotective, rather than requiring large quantities of all proteins. By using bioinformatics to identify the most promising candidates, the system reduces the total antigen quantity needed while maintaining vaccine effectiveness, thereby simplifying production.
Solution Approach 2:
The patent uses computational predictions and digital modeling to plan antigen production, allowing for optimized synthesis strategies. This enables the production of smaller, targeted quantities of specific antigens rather than large quantities of all proteins, reducing production complexity and cost.
4Ease of manufacture
If the empirical approach is used for vaccine development, then traditional methods can be maintained, but the approach demands extreme amounts of proteins and is expensive
Solution Approach 1:
The patent performs preliminary bioinformatics analysis to predict which proteins are most likely to be immunoprotective before initiating large-scale protein production. This preliminary filtering action reduces the total protein quantity needed by focusing resources only on the most promising candidates identified through computational methods.
Solution Approach 2:
The patent replaces parts of the traditional empirical mechanical testing process with computational and bioinformatics methods. Digital modeling and predictive algorithms substitute for physical protein production and testing, significantly reducing the amount of physical protein material required while maintaining or improving development efficiency.
Data Source
AI summary
Disclosed are immunogenic proteins from Pseudomonas aeruginosa as well as nucleic acids, vectors and transformd cells useful for expression of the proteins. Also disclosed are methods for prophylaxis of infection with Pseudomonas aeruginosa using the proteins, nucleic acids, vectors or transformed cells.